Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007 ; 356 : 2457.
Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research : Guidance for industry : diabetes mellitus-evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. December 2008. URL : http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf
Hiatt WR, Kaul S, Smith RJ, et al. The cardiovascular safety of diabetes drugs-insights from the rosiglitazone experience. N Engl J Med 2013 ; 369 : 1285.